Synthesis, Hydrolytic Stability, and In Vivo Biological Effects of CABS‐1 Motifs
In search of new possibilities for influencing pain, the CABS-1 motif was taken our attention. Two C-terminal motifs of CABS-1 parent octapeptide TDIFELLK (BB21) and its C-terminal amide analog (BB22) were tested in vivo for analgesic and anti-inflammatory activity in rats. The same two substances were also introduced after antagonizing the opioid, cannabinoid CB1, and nociceptin receptors in order to establish the participation of the individual receptors in the revealed analgesic effects. An antistress effect was also sought and documented when introducing the newly synthesized molecules before/after 1 h of immobilization of the animals. The observed in vivo effects make the two newly synthesized molecules starting motifs of interest in order to obtain new structures with potential analgesic and antistress activity. In addition, the test done for their hydrolytic stability at different pH values showed that both motifs are completely stable for 72-h period. Unfortunately, both octapeptides did not show any anti-inflammatory effect in carrageenan-induced paw edema model.
Authors
- Dancho Lyubenov Danalev (ORCID: https://orcid.org/0000-0003-1193-7379)
- H. Zlatanova (ORCID: https://orcid.org/0000-0003-2555-4600)
- Boryana Borisova (ORCID: https://orcid.org/0000-0001-5234-2895)
- Stoyko Petrin (ORCID: https://orcid.org/0000-0001-8347-7039)
- Hristina Nocheva (ORCID: https://orcid.org/0000-0003-4035-7170)
- Anargyros N. Moulas (ORCID: https://orcid.org/0000-0002-4681-6174)
- Petya Romanova (ORCID: https://orcid.org/0009-0008-1046-1608)
Institutions
- University of Thessaly (GR)
- Medical University Plovdiv (BG)
- Medical University of Sofia (BG)
- University of Chemical Technology and Metallurgy (BG)
Publication Details
- Journal
- Journal of Peptide Science
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1002/psc.70152
- Primary Topic
- Neuropeptides and Animal Physiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission